Cargando…
Psychosocial Predictors of Non-Adherence and Treatment Failure in a Large Scale Multi-National Trial of Antiretroviral Therapy for HIV: Data from the ACTG A5175/PEARLS Trial
BACKGROUND: PEARLS, a large scale trial of antiretroviral therapy (ART) for HIV (n = 1,571, 9 countries, 4 continents), found that a once-daily protease inhibitor (PI) based regimen (ATV+DDI+FTC), but not a once-daily non-nucleoside reverse transcriptase inhibitor/nucleoside reverse transcriptase in...
Autores principales: | Safren, Steven A., Biello, Katie B., Smeaton, Laura, Mimiaga, Matthew J., Walawander, Ann, Lama, Javier R., Rana, Aadia, Nyirenda, Mulinda, Kayoyo, Virginia M., Samaneka, Wadzanai, Joglekar, Anjali, Celentano, David, Martinez, Ana, Remmert, Jocelyn E., Nair, Aspara, Lalloo, Umesh G., Kumarasamy, Nagalingeswaran, Hakim, James, Campbell, Thomas B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143224/ https://www.ncbi.nlm.nih.gov/pubmed/25153084 http://dx.doi.org/10.1371/journal.pone.0104178 |
Ejemplares similares
-
Outcomes among HIV-1 Infected Individuals First Starting Antiretroviral Therapy with Concurrent Active TB or Other AIDS-Defining Disease
por: Périssé, André R. S., et al.
Publicado: (2013) -
Complete genome sequence of Sulfurospirillum deleyianum type strain (5175(T))
por: Sikorski, Johannes, et al.
Publicado: (2010) -
Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial
por: Avihingsanon, Anchalee, et al.
Publicado: (2022) -
Frequency of Antiretroviral Resistance Mutations among Infants Exposed to Single-Dose Nevirapine and Short Course Maternal Antiretroviral Regimens: ACTG A5207
por: Hitti, Jane, et al.
Publicado: (2014) -
Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)
por: Bosch, Ronald J, et al.
Publicado: (2010)